CDNA - CareDx, Inc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.61
+0.10 (+0.43%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close23.51
Open23.72
Bid0.00 x 800
Ask0.00 x 800
Day's Range23.31 - 24.21
52 Week Range18.75 - 41.27
Volume735,339
Avg. Volume745,251
Market Cap1.002B
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.50
Earnings DateOct 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.20
  • GlobeNewswire

    CareDx Reports Preliminary Fourth Quarter and Full Year 2019 Results

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported preliminary financial results for the fourth quarter and full year ended December 31, 2019. Preliminary revenue for the three months ended December 31, 2019 is expected to be between $35.7 million and $36.0 million, an increase of 52% to 53% compared with $23.5 million in the fourth quarter of 2018. Product revenue in the three months ended December 31, 2019 is expected to be $5.1 million, compared to $4.6 million in the same period in 2018.

  • GlobeNewswire

    CareDx’s AlloSeq cfDNA Awarded CE Mark Approval

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.

  • GlobeNewswire

    CareDx Leadership at ASTS Meeting

    SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.

  • GlobeNewswire

    CareDx's False Advertising Complaint Upheld By Court

    SOUTH SAN FRANCISCO, Calif., Jan. 08, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.

  • GlobeNewswire

    CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Dec. 24, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx Supports Bipartisan Legislation to Protect Kidney Transplant Patients

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, applauds Congress on the introduction of bipartisan legislation in the House of Representatives that would extend Medicare coverage of immunosuppressive medications for kidney transplant recipients.

  • Should You Be Concerned About CareDx, Inc's (NASDAQ:CDNA) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About CareDx, Inc's (NASDAQ:CDNA) Historical Volatility?

    Anyone researching CareDx, Inc (NASDAQ:CDNA) might want to consider the historical volatility of the share price...

  • Is CareDx, Inc. (CDNA) A Good Stock To Buy?
    Insider Monkey

    Is CareDx, Inc. (CDNA) A Good Stock To Buy?

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was CareDx, Inc. (NASDAQ:CDNA). CareDx, Inc. (NASDAQ:CDNA) was in 22 hedge […]

  • GlobeNewswire

    CareDx to Participate in Upcoming Investor Conferences

    BRISBANE, Calif., Nov. 19, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • Did The Underlying Business Drive CareDx's (NASDAQ:CDNA) Lovely 417% Share Price Gain?
    Simply Wall St.

    Did The Underlying Business Drive CareDx's (NASDAQ:CDNA) Lovely 417% Share Price Gain?

    CareDx, Inc (NASDAQ:CDNA) shareholders might be concerned after seeing the share price drop 27% in the last month. But...

  • Thomson Reuters StreetEvents

    Edited Transcript of CDNA earnings conference call or presentation 31-Oct-19 8:30pm GMT

    Q3 2019 CareDx Inc Earnings Call

  • GlobeNewswire

    CareDx at ASN Kidney Week

    BRISBANE, Calif., Nov. 06, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx Advances Patient Care with AlloSure 3.0

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces the launch of AlloSure 3.0, the next iteration in continued transplant patient-focused improvements. CareDx continues to drive innovation in the field. CareDx has new data showing AlloSure provides more in-depth insights into patients with TCMR1A and borderline rejection.

  • All You Need to Know About CareDx (CDNA) Rating Upgrade to Strong Buy
    Zacks

    All You Need to Know About CareDx (CDNA) Rating Upgrade to Strong Buy

    CareDx (CDNA) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Benzinga

    The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ...

  • GlobeNewswire

    CareDx Reports Third Quarter 2019 Results

    BRISBANE, Calif., Oct. 31, 2019 -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically.

  • Were Hedge Funds Right About Flocking Into CareDx, Inc. (CDNA)?
    Insider Monkey

    Were Hedge Funds Right About Flocking Into CareDx, Inc. (CDNA)?

    Is CareDx, Inc. (NASDAQ:CDNA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]

  • Top Ranked Momentum Stocks to Buy for October 18th
    Zacks

    Top Ranked Momentum Stocks to Buy for October 18th

    Top Ranked Momentum Stocks to Buy for October 18th

  • GlobeNewswire

    CareDx to Announce Third Quarter 2019 Financial Results on October 31st, 2019

    BRISBANE, Calif., Oct. 17, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • We're Excited To See How CareDx (NASDAQ:CDNA) Uses Its Cash Hoard To Grow
    Simply Wall St.

    We're Excited To See How CareDx (NASDAQ:CDNA) Uses Its Cash Hoard To Grow

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • CareDx, Inc (CDNA) Shares March Higher, Can It Continue?
    Zacks

    CareDx, Inc (CDNA) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in CareDx, Inc (CDNA).

  • GlobeNewswire

    CareDx Files Patent Infringement Lawsuit Against Eurofins Viracor

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has filed a patent infringement suit against Eurofins Viracor, Inc., in the United States District Court for Delaware.  CareDx is asserting U.S. Patent No. 8,703,652, which is exclusively licensed to CareDx from Stanford University.  This patent covers non-invasive monitoring of organ transplant rejection through cell-free DNA analysis. CareDx is seeking all available remedies, including damages and injunctive relief.

  • GlobeNewswire

    CareDx Adds HistoMap To Testing Portfolio

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a strategic partnership with NanoString to develop HistoMap, a gene expression profiling (GEP) solution to identify allograft rejection in transplant biopsy tissue. Seattle-based NanoString (NSTG) is a leading provider of life science tools for translational research and molecular diagnostic products.

  • GlobeNewswire

    CareDx’s KidneyCare iBox Technology Clinically Validated in BMJ Publication

    BRISBANE, Calif., Sept. 23, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx Launches AlloSeq® Tx 17 at ASHI/BANFF Meeting

    BRISBANE, Calif., Sept. 20, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.